Related Experiment Video

Updated: May 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

Laurent Boccon-Gibod1, Egbert van der Meulen, Bo-Eric Persson

  • 1Bichat-Claude Bernard University Hospital, Department of Urology, University of Paris VII Paris, France.

Therapeutic Advances in Urology
|September 10, 2011
PubMed

Insights

Gonadotropin-releasing hormone (GnRH) antagonists offer a superior alternative to GnRH agonists for advanced prostate cancer treatment by rapidly suppressing testosterone without surges. This approach provides faster symptom relief and avoids potential adverse events associated with agonists.

Area of Science:

  • Oncology
  • Endocrinology
  • Urology

Background:

  • Androgen deprivation therapy (ADT) is standard for advanced prostate cancer, often using gonadotropin-releasing hormone (GnRH) agonists.
  • GnRH agonists have drawbacks, including initial testosterone surges and microsurges, potentially causing clinical flare.
  • GnRH antagonists offer a direct blockade of GnRH receptors, providing an alternative ADT strategy.

Purpose of the Study:

  • To review the available data on GnRH antagonists for prostate cancer treatment.
  • To compare the efficacy and safety of GnRH antagonists versus GnRH agonists.
  • To highlight the advantages of GnRH antagonists, such as rapid testosterone suppression and avoidance of clinical flare.

Main Methods:

  • Review of clinical data and studies on GnRH antagonists (degarelix, abarelix) in prostate cancer.
  • Comparison of testosterone and prostate-specific antigen (PSA) suppression profiles between GnRH agonists and antagonists.
  • Evaluation of adverse events, including testosterone surge and allergic reactions.

Main Results:

  • GnRH antagonists provide rapid and profound testosterone suppression without the initial surge or microsurges seen with GnRH agonists.
  • Antagonists lead to faster prostate-specific antigen (PSA) decline and may offer quicker symptom relief.
  • Degarelix, a newer generation antagonist, demonstrates sustained testosterone suppression without systemic allergic reactions.

Conclusions:

  • GnRH antagonists are an effective and well-tolerated option for ADT in prostate cancer.
  • The absence of a testosterone surge with antagonists may improve patient outcomes and reduce the need for antiandrogens.
  • Degarelix is a prominent GnRH antagonist with a favorable profile for managing advanced prostate cancer.
Keywords:
GnRH agonistGnRH antagonistabarelixdegarelixprostate cancer

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...